Home » Big Drug Stocks Have Rallied. Why an Analyst Says They Have More Room to Run.

Big Drug Stocks Have Rallied. Why an Analyst Says They Have More Room to Run.

by admin


Major drug stocks have gotten a lift in the past month, after trailing the overall market in 2020. There could be more upside in the group, which trades at a historically low valuation relative to the S&P 500 index.

Chris Schott, a drug analyst at J.P. Morgan, notes that big drug stocks trade on average for 13.6 times projected 2021 earnings against 21.5 times for the S&P 500 index.

The…



Source link

related posts

Leave a Comment